Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimmo Porkka

Showing results (81-90 of 142) with videos related to

Pageof 15
Sort By:
Cancer Research|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid LeukemiaYingjia Chen, Liye He, Aleksandr Ianevski, et al.
Blood Advances|January 23, 2020
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survivalOscar Brück, Olli Dufva, Helena Hohtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Future Oncology (London, England)|January 20, 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Haematologica|August 24, 2019
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell typesMuntasir M Majumder, Aino-Maija Leppä, Monica Hellesøy, et al.
Cancer Research|April 4, 2019
Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic MalignanciesPetri Pölönen, Juha Mehtonen, Jake Lin, et al.
Science Advances|February 20, 2021
Patient-tailored design for selective co-inhibition of leukemic cell subpopulationsAleksandr Ianevski, Jenni Lahtela, Komal K Javarappa, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Molecular Oncology|September 21, 2025
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemiaJoseph Saad, Rhiannon Newman, Elmira Khabusheva, et al.
Pageof 15

Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Cancer Research|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid LeukemiaYingjia Chen, Liye He, Aleksandr Ianevski, et al.
Blood Advances|January 23, 2020
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survivalOscar Brück, Olli Dufva, Helena Hohtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Future Oncology (London, England)|January 20, 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Haematologica|August 24, 2019
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell typesMuntasir M Majumder, Aino-Maija Leppä, Monica Hellesøy, et al.
Cancer Research|April 4, 2019
Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic MalignanciesPetri Pölönen, Juha Mehtonen, Jake Lin, et al.
Science Advances|February 20, 2021
Patient-tailored design for selective co-inhibition of leukemic cell subpopulationsAleksandr Ianevski, Jenni Lahtela, Komal K Javarappa, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Molecular Oncology|September 21, 2025
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemiaJoseph Saad, Rhiannon Newman, Elmira Khabusheva, et al.
Pageof 15